
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This opinion paper, developed by a multidisciplinary panel of HIV experts in 2019 reflects the group’s consensus on recommendations for various stakeholders who work to improve HIV care, including population health decision-makers (such as formulary committees, pharmacy benefit managers, and clinical advisors), advocacy organizations, and local, state, and federal policy makers.






